High consumption of Ω-3 polyunsaturated fatty acids decrease plasma homocysteine: A meta-analysis of randomized, placebo-controlled trials

Nutrition

Volumn 27, Issue 9, 2011, Pages 863-867

  Huang, Tao ^a,b   Zheng, Jusheng ^a,b   Chen, Ying ^a,b   Yang, Bin ^a,b   Wahlqvist, Mark L ^a,b,c,d   Li, Duo ^a,b  

^a ZHEJIANG UNIVERSITY   (China)

^b APCNS Centre of Nutrition and Food Safety   (China)

^c NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

^d MONASH UNIVERSITY   (Australia)

Author keywords

3 Polyunsaturated fatty acid; Fish oil; Homocysteine; Meta analysis; Randomized, placebo controlled trials

Indexed keywords

HOMOCYSTEINE; OMEGA 3 FATTY ACID; PLACEBO;

ADULT; AGED; AMINO ACID BLOOD LEVEL; CONSENSUS; CONTROLLED STUDY; DATA EXTRACTION; DIET SUPPLEMENTATION; DYSLIPIDEMIA; EFFECT SIZE; HUMAN; HYPERLIPIDEMIA; INTERVENTION STUDY; MAJOR CLINICAL STUDY; META ANALYSIS; METABOLIC SYNDROME X; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVIEW; SCORING SYSTEM; SYSTEMATIC REVIEW;

DIETARY FATS; DIETARY SUPPLEMENTS; FATTY ACIDS, OMEGA-3; HOMOCYSTEINE; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 79960947136     PISSN: 08999007     EISSN: 18731244     Source Type: Journal    
DOI: 10.1016/j.nut.2010.12.011     Document Type: Review

References (32)

1. McCully K.S. Vascular pathology of homocysteinemia: implications for the pathogenesis of arteriosclerosis. Am J Pathol 1969, 56:111-128.
2. Huang T., Yuan G., Zhang Z., Zou Z., Li D. Cardiovascular pathogenesis in hyperhomocysteinemia. Asia Pac J Clin Nutr 2008, 17:8-16.
3. Refsum H., Ueland P.M., Nygard O., Vollset S.E. Homocysteine and cardiovascular disease. Annu Rev Med 1998, 49:31-62.
4. Blom H.J. Determinants of plasma homocysteine. Am J Clin Nutr 1998, 67:188-189.
5. Frosst P., Blom H.J., Milos R., Goyette P., Sheppard C.A., Matthews R.G., et al. A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nat Genet 1995, 10:111-113.
6. Tsai M.Y., Bignell M., Schwichtenberg K., Hanson N.Q. High prevalence of a mutation in the cystathionine beta-synthase gene. Am J Hum Genet 1996, 59:1262-1267.
7. Harker L.A., Slichter S.J., Scott C.R., Ross R. Homocystinemia. Vascular injury and arterial thrombosis. N Engl J Med 1974, 291:537-543.
8. Clarke R., Daly L., Robinson K., Naughten E., Cahalane S., Fowler B., et al. Hyperhomocysteinemia: an independent risk factor for vascular disease. N Engl J Med 1991, 324:1149-1155.
9. Kinsella J.E., Lokesh B., Stone R.A. Dietary n-3 polyunsaturated fatty acids and amelioration of cardiovascular disease: possible mechanisms. Am J Clin Nutr 1990, 52:1-28.
10. Li D., Mann N.J., Sinclair A.J. A significant inverse relationship between concentrations of plasma homocysteine and phospholipid docosahexaenoic acid in healthy male subjects. Lipids 2006, 41:85-89.
11. Li D., Yu X.M., Xie H.B., Zhang Y.H., Wang Q., Zhou X.Q., et al. Platelet phospholipid n-3 PUFA negatively associated with plasma homocysteine in middle-aged and geriatric hyperlipaemia patients. Prostaglandins Leukot Essent Fatty Acids 2007, 76:293-297.
12. Zeman M., Zak A., Vecka M., Tvrzicka E., Pisarikova A., Stankova B., et al. N-3 fatty acid supplementation decreases plasma homocysteine in diabetic dyslipidemia treated with statin-fibrate combination. J Nutr Biochem 2006, 17:379-384.
13. Grundt H., Nilsen D.W., Mansoor M.A., Hetland O., Nordoy A. Reduction in homocysteine by n-3 polyunsaturated fatty acids after 1 year in a randomised double-blind study following an acute myocardial infarction: no effect on endothelial adhesion properties. Pathophysiol Haemost Thromb 2003, 33:88-95.
14. Olszewski A.J., McCully K.S. Fish oil decreases serum homocysteine in hyperlipemic men. Coron Artery Dis 1993, 4:53-60.
15. Brude I.R., Finstad H.S., Seljeflot I., Drevon C.A., Solvoll K., Sandstad B., et al. Plasma homocysteine concentration related to diet, endothelial function and mononuclear cell gene expression among male hyperlipidaemic smokers. Eur J Clin Invest 1999, 29:100-108.
16. Jadad A.R., Moore R.A., Carroll D., Jenkinson C., Reynolds D.J., Gavaghan D.J., et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary?. Control Clin Trials 1996, 17:1-12.
17. Egger M., Davey Smith G., Schneider M., Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997, 315:629-634.
18. Piolot A., Blache D., Boulet L., Fortin L.J., Dubreuil D., Marcoux C., et al. Effect of fish oil on LDL oxidation and plasma homocysteine concentrations in health. J Lab Clin Med 2003, 141:41-49.
19. Benito P., Caballero J., Moreno J., Gutierrez-Alcantara C., Munoz C., Rojo G., et al. Effects of milk enriched with omega-3 fatty acid, oleic acid and folic acid in patients with metabolic syndrome. Clin Nutr 2006, 25:581-587.
20. Carrero J.J., Lopez-Huertas E., Salmeron L.M., Baro L., Ros E. Daily supplementation with (n-3) PUFAs, oleic acid, folic acid, and vitamins B-6 and E increases pain-free walking distance and improves risk factors in men with peripheral vascular disease. J Nutr 2005, 135:1393-1399.
21. Carrero J.J., Fonolla J., Marti J.L., Jimenez J., Boza J.J., Lopez-Huertas E. Intake of fish oil, oleic acid, folic acid, and vitamins B-6 and E for 1 year decreases plasma C-reactive protein and reduces coronary heart disease risk factors in male patients in a cardiac rehabilitation program. J Nutr 2007, 137:384-390.
22. Beavers K.M., Beavers D.P., Bowden R.G., Wilson R.L., Gentile M. Omega-3 fatty acid supplementation and total homocysteine levels in end-stage renal disease patients. Nephrology (Carlton) 2008, 13:284-288.
23. Pooya S., Jalali M.D., Jazayery A.D., Saedisomeolia A., Eshraghian M.R., Toorang F. The efficacy of omega-3 fatty acid supplementation on plasma homocysteine and malondialdehyde levels of type 2 diabetic patients. Nutr Metab Cardiovasc Dis 2009, 20:326-331.
24. Carrero J.J., Lopez-Huertas E., Salmeron L.M., Ramos V.E., Baro L., Ros E. Simvastatin and supplementation with n-3 polyunsaturated fatty acids and vitamins improves claudication distance in a randomized PILOT study in patients with peripheral vascular disease. Nutr Res 2006, 26:637-643.
25. Grundt H., Nilsen D.W., Hetland O., Mansoor M.A., Aarsland T., Woie L. Atherothrombogenic risk modulation by n-3 fatty acids was not associated with changes in homocysteine in subjects with combined hyperlipidaemia. Thromb Haemost 1999, 81:561-565.
26. Holdt B., Korten G., Knippel M., Lehmann J.K., Claus R., Holtz M., et al. Increased serum level of total homocysteine in CAPD patients despite fish oil therapy. Perit Dial Int 1996, 16(suppl 1):S246-S249.
27. Huang T., Wahlqvist M.L., Li D. Docosahexaenoic acid decreases plasma homocysteine via regulating enzyme activity and mRNA expression involved in methionine metabolism. Nutrition 2010, 26:112-119.
28. Finkelstein J.D. The metabolism of homocysteine: pathways and regulation. Eur J Pediatr 1998, 157:S40-S44.
29. Finkelstein J.D. Pathways and regulation of homocysteine metabolism in mammals. Semin Thromb Hemost 2000, 26:219-225.
30. Green P.S., Mendez A.J., Jacob J.S., Crowley J.R., Growdon W., Hyman B.T., et al. Neuronal expression of myeloperoxidase is increased in Alzheimer's disease. J Neurochem 2004, 90:724-733.
31. Chen L., Ingrid S., Ding Y.G., Liu Y., Qi J.G., Tang C.S., et al. Imbalance of endogenous homocysteine and hydrogen sulfide metabolic pathway in essential hypertensive children. Chin Med J (Engl) 2007, 120:389-393.
32. Huang T., Tucker K., Lee Y.C., Crott J., Parnell L.D., Shen J., et al. MAT1A variants modulate the effect of dietary fatty acids on plasma homocysteine concentrations. Nutr Metab Cardiovas 2010, Epub ahead of print.